loading
Repare Therapeutics Inc stock is traded at $1.32, with a volume of 34,174. It is up +0.00% in the last 24 hours and up +3.13% over the past month. Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
34,174
Relative Volume:
0.12
Market Cap:
$56.61M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.5919
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
-1.49%
1M Performance:
+3.13%
6M Performance:
-53.02%
1Y Performance:
-57.42%
1-Day Range:
Value
$1.31
$1.33
1-Week Range:
Value
$1.29
$1.39
52-Week Range:
Value
$0.89
$4.29

Repare Therapeutics Inc Stock (RPTX) Company Profile

Name
Name
Repare Therapeutics Inc
Name
Phone
(857) 412-7018
Name
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Name
Employee
129
Name
Twitter
@reparerx
Name
Next Earnings Date
2023-08-09
Name
Latest SEC Filings
Name
RPTX's Discussions on Twitter

Compare RPTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RPTX
Repare Therapeutics Inc
1.32 57.05M 51.13M -93.80M -129.10M -2.23
Biotechnology icon
ONC
Beigene Ltd Adr
241.99 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
435.15 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.31 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.24 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.39 5.92B 0 -153.72M -103.81M -2.00

Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-09-23 Upgrade Stifel Hold → Buy
Feb-03-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-06-23 Initiated CapitalOne Overweight
Apr-12-22 Downgrade Stifel Buy → Hold
Mar-17-22 Resumed Goldman Buy
Sep-23-21 Initiated Stifel Buy
Sep-13-21 Initiated H.C. Wainwright Buy
Jun-28-21 Initiated Guggenheim Buy
Mar-01-21 Initiated Berenberg Buy
Oct-28-20 Initiated Northland Capital Outperform
Jul-14-20 Initiated Cowen Outperform
Jul-14-20 Initiated Goldman Neutral
Jul-14-20 Initiated Morgan Stanley Overweight
Jul-14-20 Initiated Piper Sandler Overweight
View All

Repare Therapeutics Inc Stock (RPTX) Latest News

pulisher
May 19, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) is MPM Asset Management LLC's 6th Largest Position - MarketBeat

May 19, 2025
pulisher
May 19, 2025

MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat

May 19, 2025
pulisher
May 16, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World

May 16, 2025
pulisher
May 14, 2025

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News

May 14, 2025
pulisher
May 14, 2025

RPTX Advances Pipeline with Strategic Partnership | RPTX Stock N - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tower Research Capital LLC TRC Purchases 23,127 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 14, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business - citybiz

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - ADVFN

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Re - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates - TipRanks

May 13, 2025
pulisher
May 07, 2025

Repare Therapeutics Inc’s Market Journey: Closing Weak at 1.33, Down -5.00 - DWinneX

May 07, 2025
pulisher
May 07, 2025

Marshall Wace LLP Decreases Stake in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

JPMorgan Chase & Co. Boosts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 06, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Has $455,000 Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 04, 2025
pulisher
May 02, 2025

Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo

May 02, 2025
pulisher
May 01, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

May 01, 2025
pulisher
May 01, 2025

Repare Therapeutics Inc. Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News

May 01, 2025
pulisher
May 01, 2025

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace

May 01, 2025
pulisher
Apr 29, 2025

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Apr 29, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat

Apr 25, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News

Apr 25, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Repare Therapeutics Inc (RPTX) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Apr 23, 2025
pulisher
Apr 21, 2025

B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 16, 2025

Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics - Investing.com UK

Apr 16, 2025
pulisher
Apr 12, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock By Investing.com - Investing.com India

Apr 12, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock - Investing.com

Apr 11, 2025
pulisher
Apr 04, 2025

Repare Therapeutics Stock Hits 52-Week Low at $0.98 Amid Market Challenges - Investing.com

Apr 04, 2025
pulisher
Apr 03, 2025

Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals

Apr 03, 2025
pulisher
Apr 01, 2025

Repare Therapeutics details discovery of PLK4 inhibitor RP-1664 - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Appoints Steve Forte CEO - citybiz

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics appoints CFO as new CEO - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Names Forte as President, CEO - MarketWatch

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Announces Leadership Transitions - Business Wire

Mar 31, 2025

Repare Therapeutics Inc Stock (RPTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.48
price down icon 0.94%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Cap:     |  Volume (24h):